Actively Recruiting
Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.
Led by Institut Bergonié · Updated on 2026-01-30
50
Participants Needed
1
Research Sites
217 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Single-centre, retrospective and prospective observational study. This study aims to evaluate the dose delivered by radiation to the tumour and organs at risk, as a factor predicting response and the appearance of toxicities. Dosimetric calculations are made for each treatment using scintigraphic images acquired following injection of 177Lu-PSMA-617.
CONDITIONS
Official Title
Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient aged 18 and over
- Patient with indication for or having started or completed treatment with 177Lu-PSMA-617 since 01/11/2023
- Progressive, metastatic, castration-resistant prostate cancer
- Tumor overexpressing prostate specific membrane antigen (PSMA)
- Treated with taxane chemotherapy and at least one second-generation hormone therapy (apalutamide, enzalutamide, darolutamide, abiraterone-prednisone)
- Patient able to lie still for 1 hour for image acquisition
- Patient's place of residence within 2 hours' drive from the Institut Bergonié
- Patient has not opposed the use of his/her medical data for research purposes
You will not qualify if you...
- None
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institut Bergonie
Bordeaux, France, 33600
Actively Recruiting
Research Team
N
Nadège ANIZAN
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here